Artículos por temáticas
En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.
FILTRAR POR:
Tema
Tratamiento no farmacológico
364 ARTíCULOS , VIENDO DEL 331 AL 345
Alzheimer's disease drug development: translational neuroscience strategies
Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K.
CNS Spectr. 2013 Jun;18(3):128-38. doi: 10.1017/S1092852913000023. Epub 2013 Mar 11.
0
0
0
Cell and gene therapy in Alzheimer's disease
Glat MJ, Offen D.
Stem Cells Dev. 2013 May 15;22(10):1490-6. doi: 10.1089/scd.2012.0633. Epub 2013 Mar 4.
0
0
0
[Pharmacological and non-pharmacological treatment of Alzheimer's dementia]
Wallesch CW.
MMW Fortschr Med. 2013 May 2;155(8):60-2. doi: 10.1007/s15006-013-0643-4.
0
0
0
Rivastigmine patch and massage for Alzheimer's disease patients
Satoh S, Kajiwara M, Kiyokawa E, Toukairin Y, Fujii M, Sasaki H.
Geriatr Gerontol Int. 2013 Apr;13(2):515-6. doi: 10.1111/ggi.12010.
0
0
0
Research and standardization in Alzheimer's trials: reaching international consensus
Carrillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O'Meara T, Macaulay SL, Milner A, Ellis KA, Maruff P, Rainey-Smith SR, Martins RN, Bain LJ, Head RJ; NIA/Alzheimer Association and International Wor
Alzheimers Dement. 2013 Mar;9(2):160-8. doi: 10.1016/j.jalz.2012.10.006. Epub 2012 Dec 23.
0
0
0
A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease
Peters KR, Lynn Beattie B, Feldman HH, Illes J.
Prog Neurobiol. 2013 Nov;110:114-23. doi: 10.1016/j.pneurobio.2012.12.001. Epub 2013 Jan 21.
0
0
0
Amiri H, Saeidi K, Borhani P, Manafirad A, Ghavami M, Zerbi V.
ACS Chem Neurosci. 2013 Nov 20;4(11):1417-29. doi: 10.1021/cn4001582. Epub 2013 Sep 26.
0
0
0
New treatment strategies for Alzheimer's disease: is there a hope?
Aprahamian I, Stella F, Forlenza OV.
Indian J Med Res. 2013 Oct;138(4):449-60.
0
0
0
Amieva H, Dartigues JF.
Rev Neurol (Paris). 2013 Oct;169(10):752-6. doi: 10.1016/j.neurol.2013.07.011. Epub 2013 Sep 4.
0
0
0
Animal models of Alzheimer's disease and drug development
Laurijssens B, Aujard F, Rahman A.
Drug Discov Today Technol. 2013 Sep;10(3):e319-27. doi: 10.1016/j.ddtec.2012.04.001.
0
0
0
Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU
Lyseng-Williamson KA, McKeage K.
Drugs Aging. 2013 Jan;30(1):51-8. doi: 10.1007/s40266-012-0041-0.
0
0
0
Current and emerging therapies for Alzheimer's disease
Nygaard HB.
Clin Ther. 2013 Oct;35(10):1480-9. doi: 10.1016/j.clinthera.2013.09.009.
0
0
0
Overlapped metabolic and therapeutic links between Alzheimer and diabetes
Ahmad W.
Mol Neurobiol. 2013 Feb;47(1):399-424. doi: 10.1007/s12035-012-8352-z. Epub 2012 Sep 26.
0
0
0
Intravenous immunoglobulin and Alzheimer's disease: what now?
Loeffler DA.
J Neuroinflammation. 2013 Jun 5;10:70. doi: 10.1186/1742-2094-10-70.
0
0
0
Noetzli M, Eap CB.
Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.
0
0
0
Comentarios
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:
En colaboración con:
